News & Analysis as of

Healthcare › Proposed Rules › Regulatory Oversight

Orrick, Herrington & Sutcliffe LLP

Opportunities and Risks in Remote Patient Monitoring and Remote Therapeutic Monitoring for 2026

Orrick, Herrington & Sutcliffe LLP on

The Calendar Year 2026 Medicare Physician Fee Schedule (PFS) proposed rule (see Orrick’s analysis of the proposed rule here) contains important signals for the future of remote patient monitoring (RPM) and remote therapeutic...more

Nelson Mullins Riley & Scarborough LLP

Gold Dome Report - Legislative Day 36 - March 2025

Nelson Mullins Riley & Scarborough LLP on

Unusually heavy traffic that stalled commutes to the Georgia State Capitol for many on Thursday morning may prove to be symbolic of the waning days of the 2025 Legislative Session. With many bills and resolutions still...more

White & Case LLP

US de-SPAC & SPAC data & statistics roundup - HI 2022

White & Case LLP on

US de-SPAC M&A deal value has contracted significantly during the first half of 2022, sliding from US$231.31 billion during the buoyant H1 2021 period to just US$26.29 billion for H1 2022. A wider M&A slowdown as a result of...more

Mintz - Health Care Viewpoints

Regulators Look to Increase Interoperability and Patient Access to Health Data

Mintz - Health Care Viewpoints on

Federal regulators are flexing their regulatory muscle to accelerate a long-desired but often elusive goal: the interoperability of health information technology (health IT) systems. Interoperability refers to the ability of...more

Robinson+Cole Data Privacy + Security Insider

Proposed New Rules Submitted to OMB on Information Blocking

Robinson+Cole Data Privacy + Security Insider on

On September 17, 2018, the federal Office of the National Coordinator for Health Information Technology (ONC) submitted proposed new rules to the Office of Management and Budget (OMB), entitled, “21st Century Cures Act:...more

Hogan Lovells

FDA proposes streamlining combination product regulations

Hogan Lovells on

On May 15, 2018, the Food and Drug Administration (FDA) proposed amending its product classification rules for combination products, found in 21 CFR Part 3. Generally, the proposed rule purports to clarify language in the...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide